ProQR shows RNA editing works in humans, but can AX-0810 delay liver transplantation?
ProQR Therapeutics has produced the first human target-engagement evidence for its Axiomer RNA-editing platform. The results support its mechanism, but patient benefit, long-term safety and the choice between AX-0810 and AX-0811 remain unresolved.